05 May 2026
16m
London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.